HomeNewsBusinessCompaniesStrides Arcolab eyes 30-35% growth in current year
Trending Topics
Sensex Live
PhysicsWallah IPO
Pine Labs IPO
Emmvee Photovoltaic IPO

Strides Arcolab eyes 30-35% growth in current year

In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

July 01, 2011 / 13:23 IST
Story continues below Advertisement
Remove Ad

Your browser doesn't support HTML5 video.

Strides Arcolab has received the US FDA approval for a drug that is the Polymyxin Injection. It

TAGS: #Arun Kumar #Business #Strides Arcolab
first published: Jul 1, 2011 12:53 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.